Industry & Policy News

[Radiopharm Theranostics] Radiopharm Theranostics announced that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types inluding NSCLC.

[Qualigen Therapeutics, Inc.] Qualigen Therapeutics, Inc. announced it has completed its in vivo efficacy analysis of QN-247 in solid tumors. Data demonstrated robust efficacy and no safety signals in a triple negative breast cancer model.

[Greenwich LifeSciences, Inc.] FLAMINGO-01 is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.

[NeuroD Lab] Elena Daoutsali and Ronald Buijsen from the NeuroD research group were awarded the Sargenti Research Grant, organized by the Neuroscience Research Theme. The grant was for the field of neurodegenerative diseases and made possible through a donation from the legacy of mr. Sargenti to the Leiden University Fund.

[Arcutis Biotherapeutics, Inc.] Arcutis Biotherapeutics, Inc. announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase III trial of roflumilast cream 0.15% in adults and children with atopic dermatitis.

[Orca Bio] Orca Bio announced Precision-T, its pivotal Phase III study, is open, enrolling and treating patients at clinical trial sites including Stanford Health Care, City of Hope, Winship Cancer Institute of Emory University, Sarah Cannon Research Institute, Ronald Reagan UCLA Medical Center and Oregon Health & Science University.